Literature DB >> 25034499

Serum suPAR levels help differentiate steroid resistance from steroid-sensitive nephrotic syndrome in children.

Zhaoyang Peng1, Jianhua Mao, Xuejun Chen, Fengqing Cai, Weizhong Gu, Haidong Fu, Huijun Shen, Jingjing Wang, Xia Jin, Xiujuan Zhu, Aimin Liu, Qiang Shu, Lizhong Du.   

Abstract

BACKGROUND: Soluble urokinase plasminogen activator receptor (suPAR) has been regarded as a permeability factor in proteinuria, though its role in primary nephrotic syndrome remains to be elucidated further.
METHODS: Plasma samples and clinical information from 176 children with primary nephrotic syndrome were collected and concentrations of suPAR were measured. We evaluated the correlation between suPAR concentrations and clinical features, and the value of the plasma suPAR level in predicting steroid-resistant nephrotic syndrome (SRNS).
RESULTS: There is a significant difference in plasma suPAR concentration between SRNS and steroid-sensitive nephrotic syndrome (SSNS) groups (3,744.1 ± 2,226.0 vs. 2,153.5 ± 1,167.0, p < 0.05). The area under the curve (AUC) was 0.80, with p < 0.001 for the receiver operating characteristic (ROC) curve analysis using suPAR to predict SRNS. The suspicious range for predicting SRNS was estimated to be 1,907.0 pg/ml to 3,043.5 pg/ml (χ(2) = 14.775, p = 0.001).
CONCLUSIONS: From ROC curve analysis, we demonstrated the significance of the suPAR level in predicting SRNS with a high specificity but low sensitivity. However, the clinical value of suPAR to predict steroid resistance and guide therapy remains to be investigated further.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25034499     DOI: 10.1007/s00467-014-2892-6

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  31 in total

1.  Is there clinical value in measuring suPAR levels in FSGS?

Authors:  Sanja Sever; Howard Trachtman; Changli Wei; Jochen Reiser
Journal:  Clin J Am Soc Nephrol       Date:  2013-07-25       Impact factor: 8.237

2.  suPAR and FSGS: the gap between bench and bedside.

Authors:  Maarten Naesens; Björn Meijers; Ben Sprangers
Journal:  Transplantation       Date:  2013-08-27       Impact factor: 4.939

3.  The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis.

Authors:  Björn Meijers; Rutger J H Maas; Ben Sprangers; Kathleen Claes; Ruben Poesen; Bert Bammens; Maarten Naesens; Jeroen K J Deegens; Ruth Dietrich; Markus Storr; Jack F M Wetzels; Pieter Evenepoel; Dirk Kuypers
Journal:  Kidney Int       Date:  2014-01-08       Impact factor: 10.612

Review 4.  Regulation of cell signalling by uPAR.

Authors:  Harvey W Smith; Chris J Marshall
Journal:  Nat Rev Mol Cell Biol       Date:  2010-01       Impact factor: 94.444

5.  The calcineurin-NFAT pathway allows for urokinase receptor-mediated beta3 integrin signaling to cause podocyte injury.

Authors:  Bin Zhang; Wei Shi; Juan Ma; Alexis Sloan; Christian Faul; Changli Wei; Jochen Reiser; Yun Yang; Shuangxin Liu; Wenjian Wang
Journal:  J Mol Med (Berl)       Date:  2012-09-27       Impact factor: 4.599

6.  Serum levels of soluble urokinase plasminogen activator receptor is associated with parasitemia in children with acute Plasmodium falciparum malaria infection.

Authors:  M Perch; Pe Kofoed; T K Fischer; F Có; L Rombo; P Aaby; J Eugen-Olsen
Journal:  Parasite Immunol       Date:  2004-05       Impact factor: 2.280

7.  Plasma soluble urokinase receptor levels are increased but do not distinguish primary from secondary focal segmental glomerulosclerosis.

Authors:  Jing Huang; Gang Liu; Yi-Miao Zhang; Zhao Cui; Fang Wang; Xiao-Jing Liu; Rong Chu; Ying Chen; Ming-Hui Zhao
Journal:  Kidney Int       Date:  2013-02-27       Impact factor: 10.612

8.  Mycophenolate mofetil alleviates lupus nephritis through urokinase receptor signaling in a mice model.

Authors:  C-C Cheng; Y-F Lee; J-L Lan; M-J Wu; T-Y Hsieh; N-N Lin; J-M Wang; Y-T Chiu
Journal:  Lupus       Date:  2013-03-11       Impact factor: 2.911

9.  A multicenter cross-sectional study of circulating soluble urokinase receptor in Japanese patients with glomerular disease.

Authors:  Takehiko Wada; Masaomi Nangaku; Shoichi Maruyama; Enyu Imai; Kumi Shoji; Sawako Kato; Tomomi Endo; Eri Muso; Kouju Kamata; Hitoshi Yokoyama; Keiji Fujimoto; Yoko Obata; Tomoya Nishino; Hideki Kato; Shunya Uchida; Yoshie Sasatomi; Takao Saito; Seiichi Matsuo
Journal:  Kidney Int       Date:  2014-01-15       Impact factor: 10.612

10.  Urine but not serum soluble urokinase receptor (suPAR) may identify cases of recurrent FSGS in kidney transplant candidates.

Authors:  Carlos R Franco Palacios; John C Lieske; Hani M Wadei; Andrew D Rule; Fernando C Fervenza; Nikolay Voskoboev; Vesna D Garovic; Ladan Zand; Mark D Stegall; Fernando G Cosio; Hatem Amer
Journal:  Transplantation       Date:  2013-08-27       Impact factor: 4.939

View more
  8 in total

Review 1.  Focal Segmental Glomerulosclerosis.

Authors:  Avi Z Rosenberg; Jeffrey B Kopp
Journal:  Clin J Am Soc Nephrol       Date:  2017-02-27       Impact factor: 8.237

Review 2.  Immunopathogenesis of idiopathic nephrotic syndrome in children: two sides of the coin.

Authors:  Jing Chen; Xiao-Hui Qiao; Jian-Hua Mao
Journal:  World J Pediatr       Date:  2021-03-03       Impact factor: 2.764

3.  Nephronectin (NPNT) and the prediction of nephrotic syndrome response to steroid treatment.

Authors:  Mona Mohamed Watany; Hemat El-Sayed El-Horany
Journal:  Eur J Hum Genet       Date:  2018-06-11       Impact factor: 4.246

4.  A case report of adrenocorticotropic hormone to treat recurrent focal segmental glomerular sclerosis post-transplantation and biomarker monitoring.

Authors:  Siddiq Anwar; Derek S Larson; Nima Naimi; Muhammad Ashraf; Nancy Culiberk; Helen Liapis; Changli Wei; Jochen Reiser; Daniel C Brennan
Journal:  Front Med (Lausanne)       Date:  2015-03-20

5.  Serum soluble urokinase type plasminogen activated receptor and focal segmental glomerulosclerosis: a systematic review and meta-analysis.

Authors:  Tiankui Shuai; Yan Pei Jing; Qiangru Huang; Huaiyu Xiong; Jingjing Liu; Lei Zhu; Kehu Yang; Liu Jian
Journal:  BMJ Open       Date:  2019-10-07       Impact factor: 2.692

Review 6.  Long-term Outcomes of Childhood Onset Nephrotic Syndrome.

Authors:  Rebecca Hjorten; Zohra Anwar; Kimberly Jean Reidy
Journal:  Front Pediatr       Date:  2016-05-25       Impact factor: 3.418

7.  Potential role of ACE2-related microRNAs in COVID-19-associated nephropathy.

Authors:  Ahmedz Widiasta; Yunia Sribudiani; Husna Nugrahapraja; Dany Hilmanto; Nanan Sekarwana; Dedi Rachmadi
Journal:  Noncoding RNA Res       Date:  2020-09-09

8.  Multidimensional inflammatory and immunological endotypes of idiopathic focal segmental glomerulosclerosis and their association with treatment outcomes.

Authors:  Neus Roca; Alvaro Madrid; Mercedes Lopez; Gloria Fraga; Elias Jatem; Jorge Gonzalez; Cristina Martinez; Alfons Segarra
Journal:  Clin Kidney J       Date:  2020-12-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.